Michael Friedman

Michael Friedman, Purdue Pharma’s chief executive, is portrayed through a series of encounters in which the company’s account of OxyContin collided with testimony from families and local leaders. His role in the book is not established through private reflection but through public acts and competing claims: he apologized to one grieving family, faced a federal guilty plea over the company’s marketing, and later performed community service. The account preserves the tension between his lawyer’s insistence that he did not take part in misconduct and the prosecution’s argument that corporate officers had a duty to prevent it.

Corporate Leadership and the Lee County Meeting

In March 2001, after a meeting arranged by Art Van Zee between Purdue Pharma executives and concerned family members, the company offered Lee County leaders a $100,000 grant for drug treatment and law enforcement. At the meeting, a Pennington Gap banker described how his addicted son had spent $80,000 of the family’s savings. The banker presented his son as an ordinary young man whose life had changed, and challenged the company over the volume of OxyContin it was sending to the county. Lee County had a population of about 23,000, he said, yet Purdue was supplying it with as many pills as areas five times its size. Friedman responded by expressing sympathy for the family.

The meeting did not lead to the compromise Van Zee had hoped for. At its close, Purdue executives presented a planned full-page newspaper letter disputing that the company had targeted areas such as Appalachia, that it had known of OxyContin’s abuse potential, or that the drug could readily be reformulated. Sue Ella Kobak later recalled that Van Zee had believed the company might feel empathy for the banker; instead, the family meeting had been arranged to present the company’s advertisement. Her anger at Purdue’s response became part of the confrontation, while Friedman’s brief apology remained a personal exchange inside a larger dispute over corporate responsibility.

Federal Plea and the Dispute over Responsibility

In May 2007, John Brownlee announced the federal settlement in Roanoke. Purdue Pharma would plead guilty to felony misbranding, admitting that for six years it had marketed OxyContin as less prone to abuse and less likely to cause narcotic side effects than immediate-release versions. Friedman, Paul Goldenheim, and Howard Udell would plead guilty to misdemeanor versions of the offense. The company agreed to pay $600 million in fines, and the firm would pay $34.5 million on behalf of the executives. The account describes the penalties as roughly 90 percent of the company’s profits from the drug’s launch in 1996 through its removal of language about the timed-release mechanism in 2001.

The detailed financial terms show the scale and distribution of the settlement: $276.1 million was forfeited to the federal government; $160 million resolved government health-care claims; $130 million addressed private civil claims; and further payments included $5.3 million for Virginia fraud investigations and $20 million for the state prescription-monitoring program. The executives’ fines were assessed at $19 million for Friedman, $8 million for Udell, and $7.5 million for Goldenheim, with an additional $5,000 fine for each. These amounts formed part of the settlement’s public accounting, but the plea agreement did not mean the executives would serve jail time. Their probation and community service remained subject to the sentencing judge’s approval.

At sentencing, Friedman’s lawyer argued that he had not participated in misconduct by other Purdue employees, whose statements about OxyContin had sometimes conflicted with company policy. The defense also pointed to the company’s antidiversion brochures, anti-fraud prescription pads, law-enforcement liaison unit, local law-enforcement funding, and changes to sales-representative compensation. It maintained that the government had not proved Friedman committed a criminal act and argued that imprisonment would be virtually unprecedented in such a case. In court, the defense position was that the executives should not be held personally responsible for conduct attributed to others within the company.

Randy Ramseyer, the negotiator who spoke at the proceedings, challenged that account. He said the executives’ pleas acknowledged that they had not been powerless to prevent the crime: as corporate officers, they had a duty to ensure that misbranding did not occur. He also predicted that Purdue’s public-relations effort would seek to minimize the offenses. The lawyers’ arguments, which emphasized the drug’s benefits and the limits of the executives’ personal culpability, gave that warning immediate relevance. The case therefore turns not only on what Purdue admitted, but on the contested boundary between a company’s unlawful marketing and the responsibility of the people who led it.

Sentencing in Abingdon

The sentencing hearing was planned for Abingdon, where parents who had lost children to OxyContin were invited to speak on the record. The executives arrived from Connecticut on a private jet and stayed at the historic Martha Washington Inn beside the courthouse. Their attorneys asked the judge to let them enter through a back door to avoid protesters. Judge James P. Jones ordered them to use the courthouse’s front entrance, like everyone else. The route into court became a visible contrast between the executives’ effort to avoid the crowd and the judge’s insistence that they appear openly before it.

At a rally before the hearing, parents read aloud the names of people who had died. Ed Bisch had compiled the names from memorials on his message board; the printed document had grown to more than fifty pages, and the readers’ voices broke as they worked through it. During the proceedings, Friedman and the other executives seemed stunned when Barry Meier and a photographer stood up. Goldenheim stared toward the camera, while Friedman and Udell glanced away. The scene offered no account of Friedman’s private thoughts, but it fixed his public presence within the hearing: a corporate officer facing grieving families and the record assembled around the drug.

Lee Nuss addressed the executives while holding the small brass urn containing her son Randy’s ashes. She told them that the ashes came from OxyContin and pointed out that her son was present in the courtroom in that form. A reporter thought she might throw the urn, but she waved it and returned to her seat. Nuss wanted the executives to apologize and to acknowledge that OxyContin was not a wholly new answer to pain but a more potent means of dispensing an old drug. Her address placed the consequences of the company’s conduct beside the formal terms of its plea, making the human loss impossible to reduce to the settlement’s dollar amounts.

Community Service and the Aftermath

Friedman and Udell both performed community service at the Connecticut Veterans Legal Center, which Udell had founded to help veterans with problems including evictions, dishonorable discharges, and substance-abuse-related crimes. A newspaper account described the executives’ initial service there as volunteer work. Friedman later said that the experience had been unpleasant for Udell, whom he described as scrupulously honest and careful, but that they had tried to make something constructive of it. Udell continued helping the center after completing his required hours. The account thus records service as both a consequence of the plea and work that, in Udell’s case, continued beyond the formal requirement.

Udell’s son, Jeffrey, a former federal prosecutor, remained angry about his father’s fingerprinting, supervised release, and the requirement that he check with a probation officer before crossing state lines to visit grandchildren. He repeatedly emphasized that the government had presented no proof of his father’s wrongdoing. That objection echoes, though does not settle, the defense position made for Friedman: the executives’ guilty pleas carried criminal consequences even as their families and lawyers disputed whether the individuals had personally committed wrongdoing. Judge Jones later said the executives completed their probation to his satisfaction in Connecticut, but declined to disclose details. He also stressed that opioid addiction remained a serious concern in his court, with substance-abuse cases still common.

Friedman’s portrayal remains deliberately bound to that unresolved distinction between corporate admission and personal culpability. The guilty plea established his misdemeanor conviction as part of Purdue’s settlement; his lawyer’s argument denied that he had joined the misconduct, and Ramseyer’s remarks insisted that senior officers could not evade responsibility by claiming powerlessness. The book sets those positions against the banker’s account of a son’s lost savings, the parents’ public reading of the dead, and Nuss’s urn in the courtroom. Friedman’s significance lies less in a fully elaborated personal biography than in the way these scenes make executive responsibility visible, contested, and inseparable from the consequences families brought before the court.